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Introduction
Minimally invasive procedures have become the treatment of choice for many
cardiovascular diseases, leading to a high demand for the development of new intravascular
devices such as stents. As a result, a great need exists for the preliminary assessment of tissue
responses to these newly emerging stent designs and modifications, but set-up time and a lack of
facilities and personnel limit animal studies. A three-dimensional in-vitro testing system, or
blood vessel mimic (BVM), has been developed, which allows for more efficient initial
assessments to be performed on a large number of stent modifications to direct future animal and
clinical studies toward only the most promising of these devices [1].
Current research focuses on developing BVMs that are both anatomically and
physiologically representative of arterial blood vessels, as they are the focus of many
cardiovascular treatments and therapies due to their propensity for disease. Prior to discussing
the current research, it is necessary to understand the structure and function of arteries which
BVMs aim to mimic.
The typical structure of normal arteries is comprised of three layers; intima, media, and
adventitia [2]. The innermost layer, the intima, consists of a monolayer of endothelial cells (EC)
known as the endothelium. The endothelium, playing a physiological role, serves as an antithrombogenic surface to minimize friction between the arterial wall and blood cells and prevent
platelet aggregation [3]. It is also responsible for regulating the permeability of the vessel wall
as well as the activity of arterial smooth muscle cells [3].
The middle layer, consisting of elastin sheets and smooth muscle cells (SMC), is referred
to as the media. It plays both a structural as well as physiological role as it is responsible for the
majority of the strength of the vessel as well as the regulation of circulatory dynamics [4]. As

previously alluded to, smooth muscle cells of the media respond to growth factors that are
excreted by the endothelial cells during both normal vessel repair as well as pathological
pathways such as atherosclerosis and restenosis [3].
The final, most superficial layer of the arterial vessel, or adventitia, consists mostly of
fibroblasts. This layer primarily plays a structural role as these cells produce collagen and elastic
fibers, which protect and reinforce the vessel. This layer helps maintain the vessel integrity and
ultimately prevents the expansion of the vessel beyond its limit during the systolic, or high
pressure period of the cardiovascular cycle [3].
Now that the structure and function of arteries has been reviewed, it is necessary to
discuss the initial BVM design and the direction of current and future research. Preliminary
BVMs were developed with the use of fat-derived human microvascular endothelial cells
(HMVEC) sodded on an expanded polytetrafluoroethylene (ePTFE), tubular scaffold with the
use of a perfusion bioreactor [1]. The resulting endothelial cell layer is intended to imitate the
endothelium of the tunica intima and is critical in developing an in-vitro model of a native artery.
In an effort to create a more physiologically representative model, research has focused
on the use of large vessel endothelial cells, specifically human umbilical vein endothelial cells
(HUVEC) rather than the previously mentioned HUMECs. Similarly, a dual-sodding technique
has been developed to introduce a second cell layer onto the construct using human umbilical
vein smooth muscle cells (HUVSMC) [5]. This smooth muscle cell layer is intended to mimic
the anatomical and physiological function of the tunica media as mentioned earlier.
While research has focused on increasing the physiological accuracy of other components
of the BVM system -- including scaffold material selection [6-8], the bioreactor system [9, 10],
and more -- the remainder of this paper discusses the selection of cell markers and the initial

development of staining protocols. This is necessary to determine the effectiveness of the dual
sodding technique as it pertains to maintaining the desired cellular phenotype of both HUVECs
and HUVSMCs sodded onto an ePTFE scaffold to ensure the BVM remains physiologically
accurate immediately following the cell-sodding procedure.

Background
In order to discuss the criteria used to select the cell markers to detect both the desired
HUVEC and HUVSMC phenotypes on the scaffold following the dual cell-sodding technique, it
is necessary to review the antibody targets most commonly used to identify both endothelial and
vascular smooth muscle cells.

Vascular Endothelial Cells
While there are dozens of cell markers used to identify vascular endothelial cells, both
specific and non-specific to EC, the following discusses four of the more common cell markers
used

to
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markers include vonWillebrand Factor (vWF), intercellular adhesion molecule (ICAM-1 or
CD54), platelet endothelial cell adhesion molecule (PECAM-1 or CD31), and vascular cell
adhesion molecule (VCAM-1 or CD106).
vonWillebrand Factor is a highly multimeric glycoprotein secreted by vascular ECs with
two separate biological functions -- the carrier for coagulation Factor VIII, an essential blood
clotting factor, and as the cofactor required for platelets to bind to collagen exposed when the
vessel wall is damaged [11]. These functions require the constitutive expression of vWF in

endothelium (from Weibel-Palade bodies), megakaryocytes, and connective tissue [12]. The
secretion of vWF from Weibel-Palade bodies of ECs is initiated by a very limited range of
molecules, mainly thrombin and histamine [11].
Thrombin is generated during the blood clotting process when prothrombin, secreted by
the liver into the blood stream, is cleaved [2]. HUVECs, whether in culture or sodded onto a
BVM, does not come into contact with blood at any point, and are therefore not expected to
contact thrombin anywhere throughout the BVM system. Histamine, a compound involved in
local immune response, is mostly generated and secreted in the granules in mast cells or
basophils [2], and similar to thrombin, is not expected to be present in the culture of HUVECs or
the BVM system since mast cells and basophils are not present. Since the two molecules largely
responsible for the secretion of vWF from the Weibel-Palade bodies of ECs do not exist in the
BVM system, vWF expression by HUVECs in the BVM system may be minimal, if it occurs at
all.
ICAM-1 is a transmembrane, cell-surface glycoprotein typically expressed in ECs as well
as the cells of the immune system such as macrophages and lymphocytes [13]. ICAM-1 is
present in very low concentrations in the membranes of EC, and its expression is only
upregulated on cytokine activated endothelium [14]. ICAM-1 is most often involved in the
promotion and binding of leukocytes to the endothelium during a local immune response [15].
While staining ECs for ICAM-1 is common in the literature, it is often done in
conjunction with an array of other adhesion molecules and performed when immune-mediated
cell-cell adhesion reactions are of interest [16-19].

Since ICAM-1 is only continuously

expressed at very low concentrations, rarely utilized on its own in peer-reviewed literature, not

entirely specific to vascular EC, and typically involved in immune-mediated reactions, it may not
be the optimal cell marker for identifying HUVECs in the BVM system.
VCAM-1 is another cellular adhesion molecule that is only expressed on the surface of
cytokine-activated endothelium in both large and small blood vessels [20] and, unlike ICAM-1,
is restricted to the vascular tissue [21]. It promotes the adhesion of lymphocytes, monocytes,
eosinophils, and basophils to the vascular endothelium. It is also believed to play a role in the
development of atherosclerosis and rheumatoid arthritis [20].
While the natural baseline concentrations of VCAM-1 in normal, non-pathological ECs
of the endothelium may be undetermined, it is believed that the upregulation of VCAM is highly
dependent on the presence of Tumor necrosis factor-alpha (TNF-α) and Interleukin-1 (IL-1) [21,
22]. Since VCAM may only be expressed on cytokine-activated endothelium and its regulation
may require the presence of specific factors and cytokines, its use for identifying HUVECs in the
BVM system may not be ideal. This is because TNF-α and IL-1 are not present in the BVM cell
culture or BVM media and the degree of endothelium activation in the presence of the cell
culture media used in the BVM system would need to be characterized prior to using antibodies
for VCAM. VCAM-1 expression has also been observed in other cell types, including vascular
SMCs [23]. Since the antibody chosen to identify HUVECs in the BVM system will ultimately
be used in the presence of HUVSMCs as well, VCAM-1 is not an ideal choice.
PECAM-1 is a single-membrane-spanning glycoprotein found on platelets, leukocytes,
and endothelial cells [24]. With regards to EC, it is concentrated on cell-cell borders [11], has
been shown to mediate cell-cell adhesion [25], and makes up a very large portion of the
endothelial cell intercellular junction [26]. The minimal concentration of PECAM-1 at the EC
junctions of the endothelium has been shown to be in the range of 106 molecules [24]. In-situ,

PECAM-1 is constitutively expressed on continuous endothelium of all blood vessel types [24]
and is not expressed on fibroblasts or epithelial cells [27]. PECAM-1 has been used extensively
as an immunostaining marker for identifying the ECs of blood vessels from a variety of species
[24-28]. Similarly, PECAM-1 has been utilized as an EC cell marker for a variety of tissue
engineering applications [29, 30], such as vascular grafts [31, 32], in which ECs are used,
including the HUVEC cell line [29, 33, 34].
Due to the high concentration of PECAM-1 at EC junctions and its high specificity to
vascular endothelial cells making up the endothelium of blood vessels, it may be an ideal cell
marker for its use in identifying HUVECs in the BVM system, and its expression could be
indicative of a physiologically accurate mimic of an endothelium on the scaffold. Its extensive
use in the literature for both natural tissue and engineered constructs has provided a large amount
and variety of staining protocols that could serve as a starting point for developing a protocol
suitable for the BVM system. Lastly, its use with the specific HUVEC lineage that is used in the
BVM lab ensures that successful results obtained in the past by other researchers could be
duplicated. Antibodies to PECAM-1 will be used in the remainder of this paper.

Vascular Smooth Muscle Cells
While the literature identified many cell markers used to stain for the vascular endothelial
cells of the endothelium in both pathological and non-pathological states, and though SMCs
share many lineage-specific markers, only a small amount of markers were found to be
commonly used for distinguishing vascular smooth muscle cells. The most consistently used
markers found were calponin, smooth muscle myosin heavy chain (SM-MHC) , SM22-α, and αsmooth muscle actin (α-SMA). The following discusses a brief background of each cell marker.

Calponin is a filament-associated protein that is involved in the regulation and
modulation of smooth muscle contraction and is specific to smooth muscle tissue [35]. While
calponin has been used extensively in the laboratory for identifying SMCs, a review of the
literature will find that it is rarely, if at all, used on its own for staining SMCs, but rather with a
cocktail of other SMC-specific markers such as SM22α, and α-SMA [36-38]. Also, the literature
demonstrating the use of calponin has been associated with staining malignant tissue such as
malignant myoepithelioma, a variety of carcinomas, and lesions. Since calponin does not stand
on its own as a SMC marker of normal smooth muscle tissue in the literature, it may not be ideal
for identifying HUVSMCs of the BVM system.
Smooth muscle myosin heavy chain is a major contractile protein whose expression is
believed to be exclusive to the SMC lineage [39] and highly prevalent toward the end of vascular
smooth muscle cell differentiation [40]. It’s been used, most often in conjunction with α-SMA,
to identify the smooth muscle tissue of vasculature, respiratory and gastrointestinal tracts, uterus,
bladder, and eye [41]. Antibodies to SM-MHC have not been shown to cross-react with the
myosin of skeletal muscle tissue [42]. Due to its extensive use in the literature, specificity to
SMCs, and high prevalence in vascular SMCs, SM-MHC may be suitable for identifying
HUVSMCs in the BVM system and should be considered for its use in the laboratory.
Upon first review, SM22-α, similar to SM-MHC, appeared to be a potential cell marker
for the HUVSMCs in the BVM system, as it is commonly used to identify the SMCs in smooth
muscle tissue.

However, upon further investigation, it was discovered that SM22-α is a

calponin-related protein and it is expressed in conjunction with calponin [43]. It was also
learned that SM22-α expression, though present during embryological development, is not
upregulated in vascular smooth muscle tissue until adulthood [44]. Since the SMCs of the BVM

system are isolated from umbilical vein blood, its concentration in HUVSMCs could be
questionable. SM22-α expression has also been discovered in cardiac and skeletal muscle cells
[43]. Since SM22-α expression is associated with calponin, a cell marker that has already been
determined to be non-ideal for its use in the BVM system, is not specific to only vascular smooth
muscle cells, and concentrations are not increased until adulthood, it too should not be pursued
for the BVM laboratory to identify HUVSMCs.
Alpha smooth muscle actin is a smooth-muscle specific intermediate-sized filament
prevalent in vascular smooth muscle tissue [45]. While different smooth muscle cell types
contain distinct and unique species of both contractile and cytoskeletal proteins, the greatest
variation between cell types exists in these intermediate-sized filaments [46].

By taking

advantage of this variation and the specificity of the intermediate-sized filaments to a given cell
type, an intermediate filament, or a component of the filament, specific to vascular smooth
muscle cells could be used as a cell marker to stain for the HUVSMCs in the BVM lab.
It has been shown that the smooth muscle cells of the digestive, respiratory, and
urogenital tract contain desmin and γ-type smooth muscle actin as the predominant and exclusive
filaments; α-type smooth muscle actin is not expressed in these tissue types. The intermediate
filaments of vascular smooth cells differ in that they contain abundant amounts of vimentin and
no desmin. A component believed to be exclusive to vimentin filaments, and therefore specific
to vascular smooth muscle cells, is α-smooth muscle actin [46]. Smooth muscle tissue of
different blood vessels types such as aorta, small arteries, arterioles, venules, and the vena cava
from a variety of species including human, bovine, porcine, and murine have all shown a high
expression of α-SMA [46]. Its high specificity to only vascular SMCs of all types of blood

vessels in a large variety of species suggests that α-SMA may serve as an ideal candidate for a
cell marker toward HUVSMCs in the BVM lab and should be further investigated.
Upon additional review, the reliability of α-SMA as a marker for staining vascular SMCs
has been demonstrated and is extensively used in research. Similar to the use of PECAM-1 in
identifying EC in tissue-engineering applications, α-SMA is commonly used to stain for SMCs,
including the HUVSMC lineage, in a variety of engineered vascular constructs as well [36, 47].
Due to its specificity to vascular smooth muscle cells, reliability in previous research, and
demonstrated use in staining for HUVSMCs in vascular tissue-engineering applications,
antibodies toward α-SMA will be pursued for its use in the BVM lab.

Procedure
Prior to developing an immunohistochemical staining protocol for detecting the
expression of PECAM-1 by HUVECs and α-SMA by HUVSMCs on the ePTFE scaffold
following the dual sodding method, it is necessary to determine if HUVECs and HUVSMCs
express their respective cell markers when in culture in the first place. After staining ECs and
SMCs in culture for PECAM-1 and α-SMA, respectively, both positive and negative controls
need to be established prior to using the antibodies for the IHC analysis of BVM samples.

Cell Culture of HUVECs and HUVSMCs
Both cell types were thawed and incubated separately in their respective growth media in
a 6-well plate overnight at 37⁰C and 5% CO2. Prior to cell thawing and incubation, coverslips
were placed on the bottom of each well so cells would grow on the coverslips rather than the
surface of the wells. This will allow for the easy transfer of coverslips to glass slides for the

necessary microscopy after immunohistochemical staining.

HUVSMCs were thawed and

incubated after their seventeenth passage while HUVECs were taken after having undergone
nine passages. Cell confluence was allowed to reach approximately 70-80% for both cell
cultures prior to immunofluorescent staining.

Immunofluorescent Staining of HUVECs and HUVSMCs in Culture
Following cell culture, both 6-well plates with each cell type was removed from the
incubator and placed on the laboratory bench top for staining procedure. Media was aspirated
and each well was lightly washed with PBS twice. Samples were then fixed with 5mL of
Histochoice, per well, for 30 minutes. Samples were again washed twice with PBS then
incubated for 20 minutes in 10% normal goat (Santa Cruz Biotechnology, sc-2043) and donkey
(Santa Cruz Biotechnology, sc-2044) blocking serum, for SMCs and ECs, respectively. All
dilutions were made with PBS. Wells were washed twice with PBS, then samples were incubated
for 60 minutes with a mouse monoclonal primary α-SMA antibody (Santa Cruz Biotechnology,
sc-56499) for SMCs or a goat polyclonal primary PECAM antibody (Santa Cruz Biotechnology,
sc-1506) for ECs, at a concentration of 1 ug/mL in 1% of their respective blocking serums. To
serve as negative controls, two wells per 6-well plate were incubated with PBS rather than the
primary antibody solution.
After the primary antibody incubations, samples were washed with three changes of PBS
for five minutes each. All wells were then aspirated and incubated for 45 minutes with goat antimouse (Santa Cruz Biotechnology, sc-2010) or donkey anti-goat (Santa Cruz Biotechnology, sc2024) fluorescein-conjugated secondary antibodies for the SMCs and ECs, respectively.
Secondary antibody concentrations were 1 ug/mL with 1.5% normal blocking serum and

incubation occurred with minimal light exposure. Cells were then washed three times in PBS for
five minutes. A 2 ug/mL concentration solution of Hoechst dye was prepared and 200 uL
transferred to each well to stain nuclei. Cells were incubated for 15 minutes with the Hoechst dye
and were then washed for five minutes, three times with PBS. PBS was aspirated and all
coverslips with the stained cells were removed from the wells with a razor blade. Coverslips
were transferred to glass slides, glued, and labeled accordingly.

Fluorescent Microscopy
Slides were imaged using a wide-field fluorescent microscope. Slides were viewed first
under bright light to find an area of high cell density. This area was then exposed to light using a
filter of excitation wavelength 365 nm and emission 480 nm for the Hoechst dye (nuclei)
immediately followed by exposure using a filter of excitation wavelength 494 nm and emission
518 nm for FITC, which shows the secondary antibody bound to α-SMA or PECAM, depending
on the cell type. Using ImageCapturePro, the slides’ exposure to light was recorded for one
second for Hoechst stain and ten seconds for FITC, to enable a more accurate representation of
the total fluorescence.

Image J Analysis
Images were processed using ImageJ by subtracting background and enhancing
brightness and contrast for each image. Corresponding images of Hoechst and FITC were then
merged and a compiled image was generated showing both stained nuclei and α-SMA or
PECAM-1 expression for HUVSMCs and HUVECs, respectively.

IHC Analysis of Formalin Fixed, Paraffin Embedded Murine Tissue using PECAM-1
To generate both positive and negative controls for staining with the PECAM-1 primary
antibody, an IHC protocol was performed on murine vascular tissue with and without the
presence of the antibody, respectively. An avidin-biotin complex (ABC) staining technique was
used (Santa Cruz Biotechnology, sc- 2017). Samples previously fixed in formalin and embedded
in paraffin were prepared by sectioning a thickness of six microns, incubated in xylene to remove
paraffin, and rehydrated with decreasing concentrations of ethanol. All samples were incubated
with 1.5% blocking serum for one hour. Positive controls were incubated with the same primary
antibody used during the fluorescent technique with concentrations ranging between 0.5 – 5.0
ug/mL for 30 minutes, while negative controls were incubated in only PBS. Then all samples
were incubated with a 1 ug/mL concentration of biotinylated secondary antibody for 30 minutes
and incubated with an avidin-biotin (AB) enzyme for an additional 30 minutes. Finally, samples
were incubated with a peroxidase substrate for one – ten minutes, dehydrated with increasing
concentrations of ethanol, and washed in xylene prior to mounting with a coverslip. All samples
were washed with PBS three times for five minutes each between incubating in each reagent and
an aspirating pump was used to remove PBS and reagents during the entire process. After a 24hour drying period, samples were viewed and imaged using brightfield microscopy.
Comparisons were made between positive and negative controls, and optimal concentrations of
the primary antibody and peroxidase incubation times were determined for future use.

IHC Analysis of Formalin Fixed, Paraffin Embedded Murine Tissue using α-SMA
The IHC procedure of murine vascular tissue using α-SMA to generate both negative and
positive controls for the primary antibody were identical to those used with PECAM-1. A mouse

ABC staining kit (Santa Cruz Biotechnology, sc-2023) was used rather that the goat ABC kit use
for PECAM, since the α-SMA primary antibody was a mouse monoclonal antibody. Again,
samples were incubated with and without the primary antibody. Samples receiving the primary
antibody (the same α-SMA primary antibody used during the immunofluorescent staining) used
concentrations varying between 0.5 – 5.0 ug/mL and the peroxidase incubation period varied
between one - ten minutes to determine the optimal parameters for future use. Both controls
were viewed and imaged using brightfield microscopy.

Results
Immunofluorescent staining of HUVECs and HUVSMCs in culture
Figure 1 corresponds to the immunofluorescent staining of HUVSMCs. Figure 1A, taken
at 100X magnification, is representative of the smooth muscles cells that were incubated without
the presence of the α-SMA primary antibody to serve as negative controls. The blue staining
corresponds to the Hoechst dye used to identify nuclei and confirms the presence of cells.
However, there is no green staining apparent throughout any of the entire sample.
Figures 1B and 1C correspond to the positive controls in which HUVSMCs were stained
with the α-SMA primary antibody with images taken at 100X and 400X magnification,
respectively.

Again, the blue staining corresponds to cell nuclei and, unlike the negative

controls, there is obvious green staining corresponding to the presence of α-SMA. The merged
image displays the smooth muscle actin in the cytoplasm surrounding the nuclei of each cell.
Figure 2 is representative of the immunofluorescent staining of HUVECs. Results found
with the EC staining were similar to the results obtained during the SMC staining. Figure 2A
corresponds to the negative controls in which EC were incubated without the PECAM-1 primary

Figure 1: Immunofluorescent staining of HUVSMC in culture with α-SMA. A) Negative control, HUVSMCs incubated
without a primary antibody, demonstrates no false positives. Images of HUVSMCs stained using the primary antibody to αSMA at B) 100X and C) 400X magnification show positive identification of HUVSMCs in culture expressing α-SMA

antibody. The blue stain confirms the presence of cells. There appears to be a small amount of
light green staining as well, which is not expected when incubated without a primary antibody.
There is a minimal presence and lack of intensity of this green staining. Also, the merged image
in the bottom of Figure 2A shows the presence of this green fluorescent where there are no cell
nuclei (no blue staining).

Images shown for the negative controls were taken at 40X

magnification. However, the images obtained at 100X magnification show identical results as
those represented in the figure.
Figure 2B and 2C correspond to HUVECs stained with the PECAM-1 primary antibody
serving as positive controls with images taken at 100X and 400X magnification, respectively.

Figure 2: Immunofluorescent staining of HUVECs with PECAM-1 antibody. A) Negative control, HUVECs incubated without
a primary antibody, demonstrates no false positives. Images of HUVECs stained using the primary antibody to PECAM-1 at
B) 100X and C) 400X magnification show positive identification of HUVECs in culture expressing PECAM-1.

Again, the blue staining of the cell nuclei confirm the presence of cells. Unlike the negative
controls, the green staining, representative of the presence of PECAM-1, is much more intense.
When merged with the Hoechst stain, the green fluorescent surrounds the cell nuclei rather than
randomly throughout the image, as was the case with the negative controls.

IHC Analysis of Murine Vascular Tissue with PECAM-1
Figure 3 corresponds to the immunohistochemical staining of murine tissue fixed with
formalin and embedded in paraffin. The top and bottom images in Figure 3B, taken at 100X and
400X magnitudes, respectively, correspond to the negative controls in which samples were

Figure 3: Immunohistochemical staining of formalin-fixed, paraffin-embedded murine tissue using PECAM-1. A) Murine
vascular tissue incubated in PECAM-1 antibody shows successful staining of the endothelial monolayer (images at 100X and
400X mag.). B) Negative control; identical murine tissue stained in the absence of the PECAM-1 antibody demonstrates no
false positive staining.

incubated without the presence of PECAM-1 antibody. There is no staining throughout any
portion of the tissue, including the inner wall of the lumen where ECs should be present. The
images in Figure 3A correspond to the positive controls -- samples that were incubated with the
PECAM-1 primary antibody. The bottom image of Figure 3A, taken at 400X magnification,
shows a very distinct staining of the endothelium of the tunica intima. This correlates to a
successful binding of PECAM-1 to the ECs of murine tissue and will serve as quality positive
controls.

IHC Analysis of Murine Vascular Tissue with α-SMA
Figure 4 corresponds to the immunohistochemical staining of formalin fixed murine
tissue embedded in paraffin using the α-SMA antibody to detect the vascular SMC phenotype.
Images in Figure 4B correspond to the negative controls in which the samples were not
incubated with the primary antibody. The top and bottom images of Figure 4B, taken at 100X
and 400X magnification, respectively, show no staining throughout any of the tissue. The
images in Figure 4A are representative of the samples serving as positive controls in which the
tissues were incubated in the presence of the α-SMA primary antibody. Unlike the negative
controls, there is a very distinct staining throughout the majority of the tissue, indicative of the

Figure 4: Immunohistochemical staining of formalin-fixed, paraffin-embedded murine tissue using a-SMA antibody. A)
Murine vascular tissue incubated in α-SMA antibody shows successful staining of the smooth muscle cells of the tunica
media (images at 100X and 400X mag.). B) Negative control; identical murine tissue stained in the absence of the α-SMA
antibody demonstrates no false positive staining.

presence of SMCs in the tunica media. However, the staining that occurred is not nearly as dark
as was found when staining the endothelium with PECAM-1. This could be a concern and
requires further investigation.

Conclusion
The immunofluorescent staining of HUVSMCs in culture when incubated without the
presence of the α-SMA primary antibody showed no staining throughout any of the samples.
This is to be expected and confirms that the FITC-conjugated secondary antibody did not bind to
the SMCs and that no false positives will be created when using the primary antibody. When
samples were incubated with the primary antibody, there was a distinct and intense presence of
the green fluorescent surrounding the cell nuclei of each cell. This confirms that the HUVSMCs
express α-SMA when in culture prior to any cell-sodding process. The α-SMA primary antibody
can potentially be used for the IHC analysis in the BVM lab to determine whether or not
HUVSMCs remain in the desired phenotype after the pressure-sodding technique used in the
BVM lab.
While the results for the immunofluorescent staining of HUVECs in culture were similar
to those of the HUVSMCs, the presence of green fluorescent in the negative controls could be a
concern and require further discussion. When comparing the green fluorescents between the
negative and positive controls, there are several distinct differences which will be addressed.
First, the green fluorescent of the negative controls is very dim and lacks the intensity of
the positive controls. Second, the minimal green fluorescent of the negative controls do not align
with the cell nuclei and can be found throughout the glass slides where there are no cells.

These two observations suggest that the green fluorescent of the negative controls are not
indicative of the FITC-conjugated secondary antibody binding to the ECs without the primary
antibody and that these are not false positives. If the secondary antibody was binding to the ECs
without the primary antibody, then the green staining would align at the same locations as the
blue staining of the cell nuclei, which was not the case. Rather, the very slight presence of dim
green fluorescent is likely due to poor washing after the secondary antibody incubation period
and that all of the non-bound secondary antibody was successfully removed in the washes prior
to imaging. This procedure should be attempted again, taking extra care to ensure that the PBS
washes after the secondary antibody incubation period are performed diligently.
The very high intensity of the green fluorescent in the positive controls, as well as its
alignment with all EC nuclei suggests that HUVECs express PECAM-1 when in culture prior to
any cell-sodding process and that the antibody can potentially be used for IHC analysis of
HUVECs on BVMs.
The IHC analysis of murine vascular tissue with PECAM-1 successfully generated both
positive and negative controls for the primary antibody to be used when analyzing HUVECs on
the BVM. The negative controls showed absolutely no staining throughout any of the tissue.
This also confirms that, when using the proper protocol, no background or non-specific staining
occurs. The positive controls shows what a successful staining of EC on an inner lumen will
look like and all that is required next is to optimize the protocol for staining in the presence of an
ePTFE scaffold rather than the native tissue.

Complications include ensuring the scaffold

remains adhered to glass slides during incubation periods and determining optimal primary
antibody concentrations and peroxidase incubation periods as they will more than likely differ
from results obtained with the murine tissue.

The IHC analysis of the murine vascular tissue with the α-SMA primary antibody used to
identify the vascular SMCs successfully generated negative controls. When incubated without
the primary antibody, there is no staining throughout any of the tissue. This confirms that the
secondary antibody did not bind anywhere in the tissue and that no background or non-specific
staining occurred. While the positive controls differed significantly from the negative controls,
the nature of the staining could be a concern.
Rather than the darker brown staining common with a peroxidase technique, and shown
in the PECAM-1 positive controls, the staining that occurred with α-SMA is a lighter red tint,
even at the highest antibody concentrations and longest peroxidase incubation periods. These
results could not be a consequence of secondary antibody cross-reactivity, otherwise the negative
and positive controls would be identical and the staining, if anything, would be expected to be
even darker than those obtained when staining the endothelium with PECAM-1. The same is
true of primary antibody cross-reactivity, plus the staining occurs only in the location where
SMCs are expected to reside. If primary antibody cross-reactivity was occurring, we would
expect to see staining throughout the entire tissue, not just concentrated in the tunica media.
Endogenous biotin activity could not be the factor either because, again, the negative and
positive controls would look identical.
The lighter staining that occurs with the positive controls using α-SMA is likely a result
of poor enzyme activity or primary antibody potency. It should be noted that one vial of the
primary antibody was handled poorly at some point during the shipping process from the vendor
and that a fresh vial of α-SMA antibody could result in better staining. If the problem persists, a
higher concentration of the primary antibody exceeding 5.0 ug/mL and/or a peroxidase
incubation period greater than ten minutes could be attempted. Another suggestion would be to

use an α-SMA primary antibody that was raised in a different species and would also require a
different ABC staining kit, utilizing a different secondary antibody as well. This is preferred
over using higher concentrations of the current antibody, as the reagents are expensive and need
to be used sparingly. Another suggestion would be to use antibodies toward smooth muscle
myosin heavy chain rather than the α-SMA primary antibody.
While these suggestions may generate better positive controls, they may not be necessary
when staining HUVSMCs on an ePTFE scaffold for several reasons. First, the SMCs in the
BVM system are human rather than murine. This could provide different results than those of
the murine tissue that was used for the controls, so the current mouse antibody may still work
well with BVMs. Second, there would not be a presence of a large variety of tissue types found
in the murine samples (such as different types of connective tissue) as the BVM would consist of
only the HUVSMCs, HUVECs, and the polymer scaffold. So, if the large presence of other
tissue types in the sample was a source of the problem, this would not occur with the BVM.
Lastly, the sodding density of HUVSMCs onto the BVM, and the sum of any cell division that
may occur immediately afterword is likely to be less than the total density of SMCs in the
murine tissue. So, if the problem with the α-SMA on the positive controls was that the primary
antibody concentrations were too low, not very potent, or that the peroxidase enzyme was acting
weakly, this might not be a concern when staining BVMs because there would be higher primary
antibody-to-cell and peroxidase-to-AB enzyme ratios. However, prior to optimizing the α-SMA
protocol for analyzing HUVSMCs in the BVM system, these problems with the positive controls
should be identified and addressed.
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